Valerio Therapeutics Société anonyme (FRA:C4X)

Germany · Delayed Price · Currency is EUR

0.7950

-0.0160 (-1.97%)

Last updated: Aug 26, 2026, 8:01 AM CET

1,138% (1Y)

Market Cap	404.55M +3,317.1%
Revenue (ttm)	2.57M +43.5%
Net Income	-4.90M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.7950
Previous Close	0.8110
Day's Range	0.7950 - 0.7950
52-Week Range	0.0426 - 0.9300
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 26, 2026

About FRA:C4X

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody– drug conjugates, and chimeric antigen receptors. The company was formerly known as... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1997

Employees 25

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol C4X

Financial Performance

In 2025, FRA:C4X's revenue was 2.57 million, an increase of 43.50% compared to the previous year's 1.79 million. Losses were -4.90 million, -79.53% less than in 2024.

Financial Statements